Business Wire

Pluto Labs' 'Strategic Efficiency' AI Outperforms Google & Anthropic Models at a Fraction of the Cost

16.7.2025 12:47:00 CEST | Business Wire | Press release

Share

— Achieves decisive victory in key scientific benchmarks, delivering highly practical and experimentally testable ideas with unparalleled cost-efficiency. Global commercial launch slated for Q3 2025, leveraging an existing platform of 170,000 researchers.

In the global race to create an 'AI Scientist' capable of independent scientific discovery, Korean startup Pluto Labs is making significant waves. While tech giants like Google and Anthropic define competitive strength by sheer computing power, Pluto Labs introduces 'Scinapse AI,' a groundbreaking model that develops a more effective AI Scientist at just one-tenth of the usual computational cost, achieving overwhelming performance against top models in blind evaluations.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715211709/en/

GRAPH: Scientific Idea Generation Performance Comparison - Scinapse AI vs. Google Gemini 2.5 Pro vs. Claude Opus 4 (Evaluation conducted by Pluto Labs)

Pluto Labs pioneers a 'Strategic Efficiency' architecture, mirroring how human scientists optimize research. Instead of brute-force computing (like Google's 'Co-scientist'), Scinapse AI smartly delegates inefficient tasks, such as sifting through vast data, to its existing Scinapse academic search system (used by 170,000 researchers). This allows the AI to focus exclusively on creative reasoning and generating new ideas, leading to unparalleled practicality and cost-efficiency.

Scinapse AI's superior performance was proven in blind evaluations judged by direct competitors' AI models (OpenAI O3, Anthropic's Claude 4 Opus, and Google's Gemini 2.5 Pro). Scinapse AI consistently ranked #1 in 'Plausibility' (how realistic and sound an idea is) and 'Testability' (how easily an idea can be experimentally validated) across 61 diverse scientific topics. This confirms Scinapse AI delivers "real scientific hypotheses that are practical to implement and can be experimentally validated within 3-5 years," a significant leap from 'plausible fiction' to 'actionable scientific research.'

Pluto Labs has developed a robust system to eliminate AI 'hallucinations' (false information), a critical barrier in scientific AI. All Scinapse AI ideas are strictly grounded in a database of 260 million academic papers. The system dynamically refines searches for highly accurate data and rigorously cross-references ideas against the database to guarantee genuine novelty, identifying truly new scientific insights. "It provides the most complete answer to the question that challenges researchers most: 'Is this idea truly new?'" said Professor Changshin Jo of POSTECH. "The AI completes a literature review in minutes that would take a human researcher days or weeks, and with higher accuracy. This is not just an idea-generation tool; it's an innovation that fundamentally changes the starting point of research planning."

With cumulative funding of 5 billion KRW (~$3.6M USD), Pluto Labs is uniquely positioned to disrupt the global 'AI Scientist' race. Its 'efficiency' and 'practicality' approach, combined with its established Scinapse platform, sets it apart. "The fact that a small Korean startup has proven superior to Google in an objective benchmark is more than just a technical achievement—it's a symbolic event for innovative leadership," said Simon Kim, CEO of Hashed. "It demonstrates that success in advanced AI can be achieved through creative problem-solving and strategic design, not just infinite capital. This is a significant milestone that points to the future direction for the global AI ecosystem, suggesting a new path for AI agent development." Scinapse AI is slated for official global launch in Q3 2025.

About Pluto Labs:

Pluto Labs is a Seoul-based Research Intelligence service company founded in 2019 that specializes in AI-powered scientific research tools. The company operates Scinapse, a comprehensive academic search platform used by over 170,000 researchers worldwide. Scinapse AI, launching in Q3 2025, is a next-generation AI scientist system that generates research ideas with high scientific validity through a hybrid AI architecture while maintaining cost efficiency. The company has raised a cumulative 5 billion KRW (~$3.6M USD) in funding from investors including Hashed, JB Investment, HG Initiative, and POSCO Investment. Pluto Labs is committed to leading global research innovation through accessible AI solutions.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250715211709/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye